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Summary The nm23-HJ gene is a putative metastasis-suppressor gene encoding a 17 kDa protein with
nucleoside diphosphate kinase activity. Expression of nm23-H1/NDPK-A correlates inversely with the
metastasising potential of some human tumours and experimental animal cells. No nm23 expression studies
exist for human malignant lymphomas so far. In this study, we examined nm23-HJ expression by Northern and
immunohistochemical analysis in 106 primary lymphoma samples from patients with Hodgkin's disease (HD)
(n = 15), high-grade non-Hodgkin's lymphoma (NHL) from different lineages (n=71) and low-grade NHL
(n =20). Both inter- and intra-subtype variations in nm23-HI/NDPK-A expression levels were demonstrated by
all disease subtypes. Besides this heterogeneity, a general trend towards highly malignant samples expressing
higher nm23-HJ/NDPK-A levels than the low-grade lymphomas was observed. Both adult and childhood HD
and high-grade NHL samples exhibited significantly higher NDPK-A expression than the low-grade NHL
found only in adults. High nm23-HJ/NDPK-A levels in lymphoma samples did not always reflect proliferative
activity of tumour cells as monitored by Ki-67 antigen staining. Fifty samples were further investigated for
possible mutations in the nm23-HJ coding sequence by means of reverse transcriptase-polymerase chain
reaction (RT-PCR) and single-strand conformation polymorphism (SSCP) analysis. No mutation was found
by this screening. Our results suggest a role for nm23-HJ expression in the disease aggressiveness of
lymphomas.
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The nm23 gene seems so far to be the most promising
candidate for a gene with metastasis-suppressor function. It
was originally identified in differential hybridisation experi-
ments involving murine K-1735 melanoma cell line clones of
varying metastatic potential (Steeg et al., 1988). A tumour
metastasis-suppressor function was implicated by the reduced
expression of nm23 in highly metastatic sublines compared
with non-metastatic sublines derived from the same K-1735
clone (Steeg et al., 1988; Rosengard et al., 1989; Leone et al.,
1991). Two closely related homologues of this gene, namely
nm23-HJ and nm23-H2, have been found, both of which map
to the chromosomal locus 17q21.3 (Backer et al., 1993). They
encode 18 kDa and 17 kDa proteins respectively, which have
been demonstrated to shave nucleoside diphosphate kinase
(NDPK) activity (Biggs et al., 1990; Lacombe et al., 1990;
Gilles et al., 1991). The nm23-H2 gene product was recently
shown to be the c-myc transcription factor PuF (Postel et al.,
1993). The transfection of nm23 cDNA into low nm23-
expressing and highly metastatic murine melanoma and
human breast cancer cell lines reduced their metastatic
potential, independent of growth rate, and further stratified
their suppressor role in these tumour cohorts (Leone et al.,
1991, 1993a).
Down-regulation of the nm23-HJ gene expression due to
mutation and its allelic deletion at the 17q21.3 chromosomal
locus, which might abrogate its suppressor role, has been
implicated in metastasis formation of some human tumour
types (Bevilacqua et al., 1989; Cohn et al., 1991; Hennessy et
al., 1991; Hirayama et al., 1991; Leone et al., 1991;
Nakayama et al., 1992). In human breast carcinoma,
reduced primary tumour nm23 expression has been shown
to correlate with disease recurrence (Hirayama et al., 1991),
significant reductions in survival (Barnes et al., 1991;
Hennessy et al., 1991) and the presence of lymph node
metastases in one of three reported studies (Bevilacqua et al.,
1989; Sastre-Garau et al., 1992; Dawkins et al., 1993). This
inverse correlation between low nm23-HJ/NDPK-A expres-
sion and some clinicopathological features has also been
found in several other tumours studied, including human
hepatocellular carcinoma (Nakayama et al., 1992) and
melanoma (Florenes et al., 1992). In other cancer types,
however, nm23-HJ/NDPK-A may be irrelevant to metastatic
tumour progression, or it may be altered by means other than
reduced expression. In childhood neuroblastoma, for exam-
ple, nm23 mutations have been found, and aggressive N-myc-
amplified stage III and IV tumours have been reported to
express relatively high levels of Nm23-HI/NDPK-A (Leone
et al., 1993b; Chang et al., 1994; Hailat et al., 1991).
Similarly, higher Nm23-Hl/NDPK-A expression levels have
been correlated with high grade of malignancy in other
neoplastic diseases, such as small-cell lung carcinomas (Engel
et al., 1993) and prostate cancers (Igawa et al., 1994).
Malignant lymphomas, Hodgkin's disease (HD) and non-
Hodgkin's lymphomas (NHL) constitute a heterogeneous
group of disorders. NHL comprise tumours of different
histogenesis and variable clinical outcomes. The indices most
commonly used in the study of NHL, i.e. histological
classification and staging, give an estimate of the average
prognosis but do not accurately predict clinical outcome in
individual cases. This is reflected within each of the major
subgroups of this disease, i.e. low-grade and high-grade
lymphomas, in which a great variation in the clinical pattern
exists (Horning and Rosenberg, 1984; Gaynor and Ultmann,
1984). Consequently, there is a need for reproducible
quantitative methods of tumour description to confer
additional prognostic information and so guide the clinician
in the selection of the most appropriate therapeutic approach.
The aim of this study was to determine in a large series of
primary childhood and adult lymphomas the pattern of
nm23-HJ expression as the basis for future evaluation as a
probable prognostic indicator, and whether the nm23-HJ
gene is mutated in some of these tumour subtypes. As it has
been shown that low proliferative activity was associated with
low-grade NHL while high proliferative activity was
associated with high-grade NHL (Kath et al., 1995), we
also checked whether there exists a correlation of nm23-HJ/
NDPK-A expression to proliferative activity in the lympho-
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Table I Relative staining intensities [Mean values (range)] for nm23-HI/NDPK-A and Ki-67 antigen in lymphomas as
tested on paraffin sections withMAb 37.6 (recognises only nm23-HJ/NDPK-A) and MIB-l (recognises the Ki-67 antigen)
All cases Cases aged 0.5-20years (median IOyears)
Lymphoma typea . n MAb37.6 MIB-1 n MAb37.6 MIB-1
Low-grade NHL
B-cell CLL 7 1.4(1-2) 1.0(1 -1) - - - -
Lymphoplasmacytoid 4 2.5(1-3) 1.0(1 -1) - - - -
Mantle cell 5 3.0(3-3) 1.4(1-3) - -
FCL (diffuse) 1 2.0(2-2) 1.0(1 -1) - - - -
FCL (follicular) 3 2.3(2-3) 1.0(1 -1) - - - -
High-grade NHL
Diffuse LBCL 10 3.1(3-4) 2.0(1-4) 2 3.0(3-3) 3.0(2-4)
Precursor B-LL 18 2.7(1-4) 3.4(2-4) 14 2.5(1-4) 3.4(2-4)
Burkitt's 13 3.4(2-4) 4.0(4-4) 12 3.3(2-4) 4.0(4-4)
ALCL 4 3.3(3-4) 2.5(2-3) 4 3.3(3-4) 2.5(2-3)
Precursor T-LL 11 3.0(3-3) 3.7(3-4) 9 3.0(3-3) 3.7(3-4)
PTCL (LN, NOS) 4 3.3(3-4) 2.8(2-4) - - - -
PTLC (LN, Mf/SS) 4 2.5(2-3) 1.3(1-2) - - - -
PTCL (skin, NOS) 5 2.6(2-3) 1.4(1-2) - - - -
PTCL (Mf/SS) 2 3.0(2-4) 2.0(1-3) - - - -
Hodgkin's lymphomas
Lymphocyte-rich 2 3.0(3-3) 1.0(1 1)
Nodular sclerosing 7 3.4(3-4) 2.8(1-4) 3 3.0(3-3) ND
Mixed cellularity 4 3.5(3-4) 3.3(2-4) 2 3.5(3-4) 3.0(2-4)
Lymphocyte depleted 2 3.0(3-3) 1.0(1 -1) 1 3.0(3-3) ND
aLN, lymph node; NOS, not otherwise specified; Mf/SS, mycosis fungoides/Sezary's syndrome. n, number ofsamples. ND,
not done.
mas analysed. Finally, as the clinical spectrum of childhood
NHL is different from that in adults, with frequent
extranodal involvement, we checked for possible differences
in nm23-HJ expression patterns between the two age groups.
Materials and methods
Tissue samples
Tumour tissue was collected from 106 patients between 1987
and 1993. The diagnosis of HD and NHL was established
using standard morphological and immunohistochemical
criteria. Low- and high-grade non-Hodgkin's lymphomas
were classified according to the Revised European American
Classification of Lymphoid Neoplasms (REAL) classification
(Harris et al., 1994). Low-grade NHL comprised small
lymphocytic lymphomas, lymphoplasmacytoid, mantle cell
lymphoma and follicle centre lymphoma (FCL). High-grade
NHL comprised diffuse large B-cell lymphoma (diffuse
LBCL), precursor B-lymphoblastic lymphoma (precursor B-
LL), Burkitt's lymphoma, anaplastic large-cell lymphoma
(ALCL) of T and null cell types and peripheral T-cell
lymphoma (PTCL). Hodgkin's disease consisted of lympho-
cyte-rich (LR), nodular scleroses (NS), mixed cellularity
(MC) and lymphocyte-depleted (LD) subtypes.
Childhood NHL patients were aged 0.5-20 years (median
10 years) while adult NHL patients were aged 23-85 years
(median 61 years). Sixty-six of the patients were male and 40
female. Seventy-one patients presented with nodal disease
and 35 had extranodal lymphoma. Tissue samples were
subdivided for study and routine histopathological examina-
tions. Study samples were snap-frozen in liquid nitrogen and
stored at -70°C until processing.
Immunohistochemical staining
Formalin-fixed and paraffin-embedded tissue sections (3 gm)
from 106 patients were stained for NDPK-A with the anti-
nm23-HJ/NDPK-A monoclonal antibody MAb 37.6 at a
dilution of 1:100 (1 mg ml-' stock) in 1 x phosphate-
buffered saline (PBS). This antibody was generated as has
been previously described (Aryee et al., 1995). It does not
cross-react with NDPK-B on Western blot and showed the
appropriate band at 18 kDa. The immunoreactivity was
investigated by a three-step immunoperoxidase procedure
(ABC-Elite, Vector, Burlingame, CA, USA) according to the
manufacturer's recommendations. Briefly, sections were
deparaffinised and endogenous peroxidase activity was
blocked using 0.3% hydrogen peroxide in methanol. After
treatment with normal blocking serum, sections were
incubated with the NDPK-A specific monoclonal antibody
37.6. Sections of normal lymph nodes and benign unspecific
lymphadenitis served as staining controls. The peroxidase
reaction used 0.02% 3,3'-diaminobenzidine tetrahydrochlor-
ide in the presence of hydrogen peroxide. Sections were
counterstained with Mayer's haemalum.
Staining results for lymphoma specimens were evaluated
semiquantitatively by two observers blind to nm23-HJ RNA
data, taking into account the percentage ofNDPK-A-positive
neoplastic cells (which always paralleled staining intensity as
determined relative to adjacent non-tumorous lymphocytes or
plasma cells), as (0) <5%, (1) 5-20%, (2) 20-50%, (3) 50-
90% and (4) >90% positive-staining cells. Representative
results of immunohistochemistry are shown in Figure 2 and
summarised in Table I. The proliferative activity was
evaluated using the Ki-67 specific monoclonal antibody
MIB-1 (Dianova Hamburg, dia 505, dilution 1:10).
Statistical analyses were carried out using the non-
parametric Kruskal-Wallis analysis of variance. A P-value
less than 0.05 was considered to be statistically significant.
Northern blot analysis
Total RNA was extracted from primary snap-frozen
lymphoma samples using the guanidinium isothiocyanate/
phenol method according to Chomcynzki et al. (1987). Five
micrograms of total RNA was resolved by electrophoresis on
1.2% agarose-formaldehyde gel and transferred onto
Hybond N membrane (Amersham, Aylesbury, UK) accord-
ing to standard protocols. Prehybridisation and hybridisation
reactions were performed at 42°C in 50% (v/v) formamide,
5x standard saline citrate (SSC), 50 mM Tris-HCl, pH 7.5,
5 x Denhardt's solution, 5% (w/v) sodium dodecyl sulphate
(SDS), and 250 jMg ml-' denatured salmon sperm DNA and
washed at a final stringency of 0.1 x SSC and 0.1% (w/v)
SDS at 65°C. The blot was hybridised with a 32P-labelled
cDNA fragment corresponding to a portion of the 3'-
untranslated region specific for nm23-HJ (Stahl et al.,
1991), and hybridisation was detected by autoradiography.
For multiple hybridisations, the bound probe was removednm23-Hl mRNA and protein expression in lymphomas
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by incubating the filter twice for Omin in 0.1 x SSC and
0.1% SDS at 95-100C. Quality and the comparable loading
of RNA samples were confirmed by including ethidium
bromide in the gels and by rehybridisation to ,B-actin cDNA
respectively.
PCR/SSCP analysis and DNA sequencing
Three sets of primers were used separately for polymerase
chain reaction (PCR) amplification of overlapping fragments
from first-strand complementary DNA covering the entire
coding sequence of nm23-HL. They were;
(1) nmSl: 5'-TGCTGCGAACCACGTGGGTC-3' and
nmAl: 5'-GGACGGTCCTTCAGGTCAAC-3'
(2) nmS2: 5'-GCTTCCGAAGATCTTCTCAAGA-3' and
nmA2: 5'-CCAGTTCCTCAGGGTGAAACC-3'
(3) nmS3: 5'-GCAGAGAAGGAGATCGGCTTG-3' and
nmA3: 5'-CAGATGGTCGGGGATGGTAAC-3'.
Primers were selected on the basis of limiting the fragment
sizes to less than 300 bp for SSCP analysis. Polymerase chain
reactions were done using 1 pl of the first-round cDNAs with
the appropriate primers in the presence of [32P]dCTP
(3000 Ci mmol-') (Dupont NEN, Boston, MA, USA) in a
50 pl reaction volume as recommended by the manufacturer
(Perkin Elmer Cetus, Norwalk, CT, USA). The following
amplification conditions were used: 30 cycles of94°C for 30 s,
62°C for 30 s and 72°C for 1 min, preceded by a 94°C,
10 min primary denaturation step and followed by a 72°C,
7 min final extension step. An aliquot of 1 p1 of each product
was subsequently diluted 1: 20 with the loading buffer (95%
formamide, 2 mM EDTA, 0.05% bromophenol blue, 0.05%
xylene cyanol) and denatured at 90°C for 5 min. A 2 p1
aliquot was loaded onto a 6% acrylamide non-denaturing
sequencing gel in 89 mM Tris-borate, 2 mM EDTA pH 8.3
and electrophoresed for 5 h at 4°C at 35 W. Gels were
subsequently dried and bands visualised by autoradiography.
DNA sequencing was performed on PCR-amplified nm23-HJ
cDNA with the same primers as described above using the
DNA cycle sequencing system (BRL, Gaithersburg, MD,
USA), according to the manufacturer's instructions.
Results
nm23-H1 mRNA expression and mutational analysis
Nm23-HJ RNA steady-state levels in 48 samples were
determined in comparison with f,-actin and 18S rRNA by
Northern blot analysis (Figure 1). Autoradiographs were
semiquantitatively evaluated by densitometry. Representative
data shown in Figure I indicate that, although both inter-
and intra-subtype variations in band intensity for the nm23-
HI 0.8 kb mRNA levels were observed, there was a trend
towards higher expression levels in the high-grade NHL
relative to the low-grade NHL. The nm23-HJ mRNA levels
in some of the high-grade NHL were similar to that of the
highly NDPK-A-expressing MCF-7 breast adenocarcinoma
cells (Figure 1). The variation of nm23-HJ gene expression
in the various lymphoma subtypes may have resulted from
mutations in the coding region of the gene. To examine such
a possibility, we screened for nm23-HJ gene mutations in 48
specimens by RT-PCR/SSCP analysis. None of the
tumours showed aberrantly migrating bands in SSCP
analysis with any of the primer sets used, which spanned
the whole coding region. Twenty-four cDNA samples
generated by PCR, representing the various lymphoma
subtypes studied, were randomly chosen and the coding
regions sequenced. None of these specimens harboured a
mutation (data not shown).
Immunohistochemical reactivity of NDPK-A
Paraffin-embedded, formalin-fixed sections from 106 resected
primary lymphomas, well preserved for immunohistochemical
analysis, were studied for tumour cell reactivity with the
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Figure 1 Representative Northern blot analysis showing the
nm23-HI mRNA levels (and their corresponding immunoreactiv-
ities) in low-grade and high-grade NHL as well as in Hodgkin's
disease. nm23-HI expression although heterogeneous, was
relatively higher in the high-grade NHL (similar to control
MCF-7 expression level) than in the low-grade NHL. Total RNA
was hybridised to nm23-HI-specific cDNA probe (top) and, as a
control, to ,B-actin (middle). As a loading control, a negative
photomicrograph of ethidium bromide-stained 18S rRNA is
shown (bottom).
NDPK-A specific antibody 37.6. Both inter- and intra-subtype
variations in NDPK-A expression were exhibited in the
immunohistochemical stainings (Figure 2), which corrobo-
rated the RNA data. Results of the immunohistochemical
analyses are summarised in Table I. Staining intensity of
neoplastic cells was compared with non-neoplastic surrounding
lymphoid tissue. Cells usually showed cytoplasmic staining.
Additional nuclear staining was observed in high-grade
lymphomas, i.e. LBCL and Burkitt's lymphoma, ALCL and
in Hodgkin's cells of mixed cellularity and NS types. In low-
grade NHL, staining was restricted to the cytoplasm.
Generally, low-grade malignant B-type NHL exhibited only
few stained tumour cells; however, mantle cell lymphomas
(Figure 2c) exhibited more positive tumour cells than the other
low-grade lymphomas (i.e. lymphocytic lymphoma, Figure 2b;
lymphoplasmacytoid lymphoma and follicle centre lympho-
mas). NDPK-A staining intensity was also higher in this group
oflymphomas known to have a more aggressive clinical course.
Within the rather heterogeneous group of precursor B-
lymphoblastic lymphomas, we found low staining intensities
in the very immature lymphomas, pre-pre-B and pre-B,
whereas more mature lymphoblastic lymphomas presented
with considerably more stained tumour cells and a higher
staining intensity. Among the other high-grade malignant B-
type NHL, almost all tumour cells exhibited strong expression
of NDPK-A. The most prominent tumour positivity and
staining intensity was observed in Burkitt's lymphoma speci-
mens (Figure 2d and Table I).
In T-cell lymphomas, two tumour sites were investigated:
nodal lymphomas and the clinically rather non-aggressive
cutaneous lymphomas. In cutaneous T-cell lymphomas
(CTCL) fewer immunoreactive cells were observed than in
lymph node lymphomas with a similar morphology (e.g.
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Figure 2 Immunohistochemical analysis of nm23-HI/NDPK-A protein (a-f) and Ki-67 antigen (g-i). (a) Benign lymphadenitis.
(b) Low-grade NHL (B-cell CLL) with relatively weak NDPK-A staining in comparison with another low-grade NHL (mantle cell
lymphoma) in (c). (d) Burkitt's lymphoma tissue (high-grade NHL) with strong NDPK-A staining. (e) A T-cell lymphoma tissue
(ALCL) exhibiting strong NDPK-A immunoreactivity. (f) HD tissue (mixed cellularity) showing very strong NDPK-A positivity of
Reed-Sternberg cells. Ki-67 antigen expression is shown in follicle centre lymphoma (follicular) (g) precursor B-lymphoblastic
lymphoma (h) and HD (i). Immunohistochemical staining with anti-NDPK-A monoclonal antibody 37.6 and MIB-1 (Ki-67 antigen)
monoclonal antibody is described in 'Materials and methods'. Scale bar 50,um.
reactive cells than the same type of nodal lymphomas). In
contrast to high-grade B-cell lymphomas, we did not find
striking discrepancies in staining intensity and positivity of
cells when looking at T-cell precursor lymphoblastic
lymphomas (Table I). Anaplastic large-cell lymphomas
(ALCL) behaved like other high-grade lymphomas, usually
presenting with high rates of intensely stained tumour cells
(Figure 2e). In lymphadenitis, which was used as control,
MAb 37.6 reactivity was observed mainly within the
cytoplasm of blasts in reactive enlarged germinal centres.
(Figure 2a). Centrocytes and mantle cells were usually not
stained. Centroblasts and, occasionally, starry-sky macro-
phages showed the highest reactivity. Within the T zones,
single blastic T cells, plasma cells and histiocytes were weakly
positive. Small lymphocytes were Mab 37.6 negative.
In Hodgkin's lymphoma, nodular sclerosing (NS) andmixed
cellularity (MC) subtypes showed marked positivity of the
Hodgkin and Reed-Sternberg cells. These neoplastic cells had
the most intense cytoplasmic staining (Figure 2f) when
compared with the staining intensities of the different cellular
components in high-grade NHL. Cells from the surrounding
infiltrates such as lymphocytes or plasma cells showed weak
staining (Figure 2F). In the lymphocyte-rich and, strikingly,
lymphocyte-depleted subtypes, NDPK-A staining intensity of
theneoplasticcellswaslowerthaninbothothersubtypesofHD.
Children usually present with high-grade lymphomas of
the B and T type or Hodgkin's disease. They commonly do
not present with low-grade lymphomas. Comparing the
results between children (<20 years) and adult cases of
each subtype, no differences were observed in either staining
patterns or intensity (Table I).
Comparison of the proliferative activity and NDPK-A
immunostaining in lymphomas
MIB-1 is a monoclonal antibody that recognises the cell
proliferation marker Ki-67 in paraffin-embedded tissues. To
determine whether NDPK-A expression correlates with the
proliferative activity, we stained all lymphoma specimens
with the MIB-1 monoclonal antibody. Figure 2 shows
representative Ki-67 antigen immunoreactivities. There was
no conistent correlation between NDPK-A activity and
proliferative activity (Table I).
Correlation between histological subtype and NDPK-A
expression
As exemplified in Figure 2 and summarised in Table I, there
was considerable variation in NDPK-A staining intensities
among the lymphoma types studied (non-parametric Krus-
kal-Wallis test; X2=20.481, P=0.0001). Both high-grade
NHL and Hodgkin's lymphoma samples exhibited signifi-
cantly higher NDPK-A expression levels than low-grade
NHL (Wilcoxon's test; P=0.0002 and P=0.0001 respec-
tively). By contrast, there was no significant difference in
NDPK-A expression between high-grade NHL and Hodg-
kin's lymphoma samples (Wilcoxon's test; P= 0.0529).
Discussion
The relationship between nm23-HI/NDPK-A and tumour
metastatic potential in various human tumours and experi-
Inm23-HI mRNA and protein expression in lymphomas
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mental model systems remains a contentious subject, with
conflicting reports from different research groups. Our data
demonstrate that nm23-HI/NDPK-A is expressed in varying
amounts in all lymphomas irrespective ofclinical presentation.
In contrast to the findings reported for some other tumours
such as breast cancer (Bevilacqua et al., 1989; Barnes et al.,
1991; Hennessy et al., 1991; Hirayama et al., 1991), in which
high nm23-H1/NDPK-A expression correlates with non-
aggressive disease, our results show that, in lymphomas, high-
level nm23-HI/NDPK-A expression is found in high-grade
subtypes, similar to the situation in Ewing tumours (Aryee et
al., 1995), neuroblastomas (Hailat et al., 1991), lung
carcinomas (Engel et al., 1993) and prostate cancers (Igawa et
al., 1994). These contrasting results might indicate that nm23-
HI can function as a suppressor gene in some types of cancer
and can be associated with tumour aggressiveness in others.
This is in agreementwith the situation incolorectal carcinomas,
in which nm23-HJ mRNA expression is correlated with
increasing colorectal cancer size and extent of local bowel
invasion and therefore is speculated to be associated with local
aggressive behaviour (Zeng et al., 1994). Contrary to
neuroblastomas, in which mutations in the nm23-HJ gene
have also been associated with advanced stages of the disease
(Chang et al., 1994), no mutations have so far been found in
any of the high-grade lymphomas analysed. Within the group
of high-grade B-cell lymphomas, usually strong expression of
NDPK-A was observed. In the heterogeneous group of
precursor B lymphoblastic lymphomas, the mature types
showed relatively higher expression levels than the immature
types (pre-pre-B and pre-B). These data might parallel the
different clinical behaviour ofthese tumours as phenotypically
mature lymphoblastic B-cell lymphomas require more aggres-
sive and different chemotherapy regimens than the immature
lymphomas.
The highest cytoplasmic staining intensity, even compared
with the reactivity in high-grade NHL, was observed in HD.
NDPK-A antigen was present on Hodgkin and Reed-
Sternberg cells, whereas the accompanying plasma cells and
lymphocytes showed only faint (ifany) staining. In the classical
forms of HD (NS, MC and LD), Hodgkin's and Reed-
Sternberg cells express activation markers such as CD30,
whereas they usually do not express T- or B-cell markers. The
high expression levels of NDPK-A by Hodgkin and Reed-
Sternberg cells might beinterpreted in different ways because of
the still enigmatic origin ofthe Hodgkin and Reed-Sternberg
cell. NDPK-A expression paralleled proliferative activity in
nodular scleroses and in the mixed cellularity form ofHD but
not in the lymphocyte-depleted subtype, which is known to
have the worst prognosis ofall HD subtypes.
The skin is a very common site for extranodal lymphoma
origin. Usually, CTCL has a more favourable clinical course
and is less aggressive than the T-cell lymphomas arising in
lymph nodes. The nodal T-cell lymphomas analysed exhibited
slightly higher NDPK-A expression levels compared with
primary skin lymphomas of the same tumour morphology.
This might reflect a correlation ofNDPK-A expression to the
clinical course of the disease subtypes. However, as the result
of small patient numbers within the individual lymphoma
subtypes, statistical evaluation of these small NDPK-A
expression differences would be inappropriate and was not
done. Although high-grade lymphomas usually have a high
proliferative fraction and tend to exhibit more positivity for
NDPK-A than low-grade lymphomas, we could not
demonstrate a consistent correlation of NDPK-A expression
with proliferation, as has been demonstrated for normal
lymphoid cells (Keim et al., 1992). There was also
considerable intra- and inter-subtype variation of Ki-67
antigen immunoreactivity. Along a gradient among low-
grade lymphomas, NDPK-A expression appeared to parallel
aggressive clinical course much more than Ki-67 staining
(proliferation index), with mantle cell lymphoma exhibiting
the highest NDPK-A expression. In addition to a general
trend towards nm23-HJ expression paralleling aggressiveness
of the different lymphoma subtypes, intra-subtype variations
in nm23-HJ/NDPK-A were frequently observed in our study.
We found neither correlation of NDPK-A expression with
patient's age nor sex. As the tumour samples used for this
study have been obtained from different centres, and most of
the patients involved have been lost for follow-up, no
statistical analysis of individual clinical courses in relation
to NDPK-A expression was performed. Consequently,
though our study underlines the biological importance of
nm23-HJ expression for lymphomas, long term prospective
studies with large numbers of patients for each histological
subtype are warranted to statistically evaluate the prognostic
significance for individual patients.
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